163 related articles for article (PubMed ID: 24953430)
1. Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Knoop RF; Sparn M; Waldmann J; Plassmeier L; Bartsch DK; Lauth M; Hudemann C; Fendrich V
Neoplasia; 2014 Jun; 16(6):463-70. PubMed ID: 24953430
[TBL] [Abstract][Full Text] [Related]
2. Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.
Plassmeier L; Knoop R; Waldmann J; Kesselring R; Buchholz M; Fichtner-Feigl S; Bartsch DK; Fendrich V
Langenbecks Arch Surg; 2013 Oct; 398(7):989-96. PubMed ID: 23989613
[TBL] [Abstract][Full Text] [Related]
3. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
[TBL] [Abstract][Full Text] [Related]
4. The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine.
Chen SM; Chieng WW; Huang SW; Hsu LJ; Jan MS
Sci Rep; 2020 Nov; 10(1):20319. PubMed ID: 33230218
[TBL] [Abstract][Full Text] [Related]
5. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Qian W; Li J; Chen K; Jiang Z; Cheng L; Zhou C; Yan B; Cao J; Ma Q; Duan W
Life Sci; 2018 Sep; 208():253-261. PubMed ID: 30053447
[TBL] [Abstract][Full Text] [Related]
6. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.
Keenan BP; Saenger Y; Kafrouni MI; Leubner A; Lauer P; Maitra A; Rucki AA; Gunderson AJ; Coussens LM; Brockstedt DG; Dubensky TW; Hassan R; Armstrong TD; Jaffee EM
Gastroenterology; 2014 Jun; 146(7):1784-94.e6. PubMed ID: 24607504
[TBL] [Abstract][Full Text] [Related]
7. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
8. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing.
Knoll L; Hamm J; Stroebel P; Jovan T; Goetze R; Singh S; Hessmann E; Ellenrieder V; Ammer-Herrmenau C; Neesse A
Neoplasia; 2024 Jul; 53():101002. PubMed ID: 38744194
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
10. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
11. Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer.
Yip-Schneider MT; Wu H; Stantz K; Agaram N; Crooks PA; Schmidt CM
BMC Cancer; 2013 Apr; 13():194. PubMed ID: 23590467
[TBL] [Abstract][Full Text] [Related]
12. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
[TBL] [Abstract][Full Text] [Related]
13. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
[TBL] [Abstract][Full Text] [Related]
14. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.
Hu G; Li F; Ouyang K; Xie F; Tang X; Wang K; Han S; Jiang Z; Zhu M; Wen D; Qin X; Zhang L
Int J Oncol; 2012 Mar; 40(3):798-806. PubMed ID: 22076649
[TBL] [Abstract][Full Text] [Related]
16. Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer.
Husain K; Centeno BA; Chen DT; Hingorani SR; Sebti SM; Malafa MP
Cancer Prev Res (Phila); 2013 Oct; 6(10):1074-83. PubMed ID: 23963802
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Yip-Schneider MT; Wu H; Hruban RH; Lowy AM; Crooks PA; Schmidt CM
Pancreas; 2013 Jan; 42(1):160-7. PubMed ID: 22699205
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel IL-5 signaling pathway in chronic pancreatitis and crosstalk with pancreatic tumor cells.
Gitto SB; Beardsley JM; Nakkina SP; Oyer JL; Cline KA; Litherland SA; Copik AJ; Khaled AS; Fanaian N; Arnoletti JP; Altomare DA
Cell Commun Signal; 2020 Jun; 18(1):95. PubMed ID: 32552827
[TBL] [Abstract][Full Text] [Related]
19. IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.
Zhuang Z; Ju HQ; Aguilar M; Gocho T; Li H; Iida T; Lee H; Fan X; Zhou H; Ling J; Li Z; Fu J; Wu M; Li M; Melisi D; Iwakura Y; Xu K; Fleming JB; Chiao PJ
Clin Cancer Res; 2016 Mar; 22(6):1432-44. PubMed ID: 26500238
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice.
Bai H; Li H; Zhang W; Matkowskyj KA; Liao J; Srivastava SK; Yang GY
Carcinogenesis; 2011 Nov; 32(11):1689-96. PubMed ID: 21859833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]